Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) have been given an average recommendation of “Buy” by the nine ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $16.00.
Several research analysts have recently weighed in on the company. Zacks Investment Research cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, February 1st. ValuEngine cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. Cowen restated a “buy” rating on shares of Adaptimmune Therapeutics in a report on Tuesday, November 6th. BidaskClub cut Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. Finally, SunTrust Banks lowered their target price on Adaptimmune Therapeutics to $12.00 and set a “buy” rating on the stock in a report on Thursday, December 13th.
In other Adaptimmune Therapeutics news, Director Lawrence M. Alleva acquired 47,280 shares of the firm’s stock in a transaction that occurred on Monday, December 17th. The shares were purchased at an average cost of $0.84 per share, for a total transaction of $39,715.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 9,897 shares of company stock worth $53,147 over the last quarter. 26.47% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADAP. SG Americas Securities LLC lifted its holdings in Adaptimmune Therapeutics by 157.3% in the fourth quarter. SG Americas Securities LLC now owns 20,004 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 12,229 shares during the last quarter. Raymond James & Associates lifted its holdings in Adaptimmune Therapeutics by 59.0% in the fourth quarter. Raymond James & Associates now owns 22,906 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 8,498 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Adaptimmune Therapeutics by 139.9% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 26,341 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 15,361 shares during the last quarter. FDx Advisors Inc. acquired a new position in Adaptimmune Therapeutics in the third quarter valued at approximately $142,000. Finally, Henry James International Management Inc. acquired a new position in Adaptimmune Therapeutics in the fourth quarter valued at approximately $144,000. Hedge funds and other institutional investors own 67.96% of the company’s stock.
Shares of Adaptimmune Therapeutics stock opened at $4.57 on Tuesday. Adaptimmune Therapeutics has a 1-year low of $3.60 and a 1-year high of $14.63.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.